Massachusetts General Hospital
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Massachusetts General Hospital sits in the top decile of US sponsors by registered trial count (#4 of 15,751 sponsors by registered trial count).
Massachusetts General Hospital: 2,032 sponsored US clinical trials, 336 recruiting.
Massachusetts General Hospital sponsors 2,032 registered US clinical trials on ClinicalTrials.gov, 336 of them currently recruiting, and 1,284 completed. 240 of these trials are in Phase 3-4 (later-stage) and 515 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 29 trials.
Top-decile sponsor footprint
Massachusetts General Hospital ranks in the top decile of sponsors by registered trial count (#4 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,032 total, page 41 of 41
Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone
NCT00181558
Biochemical Brain Changes Correlated With The Antidepressant Effect Of Thyroid Hormones
NCT00562367
Androgen Replacement Therapy in Women With Hypopituitarism
NCT00027430
Cognitive Behavioral Therapy for Adult Attention Deficit Hyperactivity Disorder
NCT00050050
Efficacy of Proactive Telephone Counseling for Pregnant Smokers Enrolled in a Managed Care Organization
NCT00181909
Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)
NCT00854139
The Partners Genetics Collaborative Study of Schizophrenia
NCT00319904
Risperidone Versus Olanzapine for Mania in Preschool Children 4 to 6 Years of Age With Bipolar Disorder
NCT00181935
Antidepressant Medication Plus Directly Observed Therapy for Improving Adherence to Antiretroviral Therapy
NCT00338767
Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian Carcinoma
NCT00157560
Postmenopausal Women Estrogen and Progesterone Infusion
NCT00455741
Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer
NCT00182052
Determining the Safety and Effectiveness of Olanzapine in Children and Adolescents
NCT00183612
Multicenter Benchmarking of Functional and Psychosocial Outcomes of Pediatric Burn Survivors
NCT00239668
Efficacy of a Fibrin Sealant in Burn Surgery
NCT00181974
Neoadjuvant Chemotherapy Using Doxorubicin and Paclitaxel in Treating Women With Large Breast Cancer
NCT00096291
Sertraline and Habit Reversal in the Treatment of Patients With Trichotillomania
NCT00118014
Bupropion for Hospitalized Smokers With Acute Cardiovascular Disease
NCT00181818
Effects of Parathyroid Hormone in Men With Osteoporosis
NCT00000427
Alendronate and/or Parathyroid Hormone for Osteoporosis
NCT00000400
Charged Particle RT for Chordomas and Chondrosarcomas of the Base of Skull or Cervical Spine
NCT00592748
High-Dose Proton/Photon RT + Surgery of Sarcomas of the Thoracic, Lumbar Spine/Sacrum
NCT00592345
Proton/Photon Rt - Benign Meningiomas(P92-13)
NCT02947984
Therapies for Treatment-Resistant Panic Disorder Symptoms
NCT00118417
Studying the Effects of 7 Days of Gonadotropin Releasing Hormone (GnRH) Treatment in Men With Hypogonadism
NCT00493961
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders
NCT00494169
Early Intervention for Children at Risk for Anxiety
NCT00865306
Paclitaxel and Radiation Therapy Plus Chemoprotection With Amifostine in Treating Patients With Stage III or Stage IV Head and Neck Cancer
NCT00003193
Treatment of T1N0 Invasive Breast Carcinoma by Local Excision Implant
NCT00977275
Psychometric Study of Outcomes Instruments
NCT00253292
Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH)and Kallmann Syndrome (KS)
NCT00392756
Galantamine-CR and Cognitive Dysfunction in Bipolar Disorder
NCT00181636
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 226 |
| Phase 2 | 289 |
| Phase 3 | 58 |
| Phase 4 | 182 |
Therapeutic Areas
What is open in the Massachusetts General Hospital pipeline
336 recruiting of 2,032 indexed (17% open); 1,284 completed (63%).
Phase mix: 240 late (III/IV) vs 515 early (I/II) (early-phase heavy).
Top condition: Depression (29 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.